Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus, Inc. develops and licenses gene-edited plant traits for seed companies rather than selling seed directly. Its proprietary high-throughput gene-editing technologies, including the Rapid Trait Development System™, are used to create productivity traits for major row crops that address yield, weed, disease, insect, nutrient-use and climate-related farming challenges.
Company news commonly covers rice herbicide-tolerance and weed-management traits, seed-company and research partnerships, sustainable ingredients work, regulatory developments for precision breeding, financial results, board composition, shareholder voting matters and capital-structure actions. Updates also describe how Cibus seeks royalty revenue from licensed traits included in customers' seed products.
Cibus, Inc. (Nasdaq: CBUS) will participate in the BMO Global Farm to Market Conference with a presentation hosted by the CEO and COO on May 16, 2024. The company utilizes gene editing technologies to enhance plant traits in seeds.
Cibus, Inc. (Nasdaq: CBUS) reported Q1 2024 financial results and business update. Key highlights include success in single cell regeneration platform for Wheat, agreements in Rice, advancing Pod Shatter Reduction trait in Canola, and recognition by Fast Company. The PR also mentions global approval momentum for new genomic techniques, regulatory shifts in EU, and appointment of a new Chief Legal Officer, Jason Stokes. Financially, the company reported a cash position of $24.5 million, increased R&D and SG&A expenses, and a net loss of $27.0 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.